Novartis to Pay Monte Rosa $150 Million Upfront to Develop New Class of Drugs
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, will pay Monte Rosa Therapeutics (NASDAQ: GLUE) $150 million upfront payment for a […]
Novartis to Pay Monte Rosa $150 Million Upfront to Develop New Class of Drugs Read More »
